Augmented Reality Vision for Surgery

Projektinformationen

ARVisS

ID Finanzhilfevereinbarung: 697613

DOI 10.3030/697613

Abgeschlossenes Projekt

EK-Unterschriftsdatum 20 Oktober 2015

Startdatum 1 November 2015

Enddatum 30 April 2016

Finanziert unter

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Gesamtkosten € 71 429,00

EU-Beitrag € 50 000,00

Koordiniert durch

TRIVISIO PROTOTYPING GMBH
Germany

Ziel

On European scale, out of an estimated 3.45 million new cases of cancer, the most common sites are female breast, colon, lung and prostate. These four cancers represent half of the overall burden of cancer in Europe, with an economic impact estimated over 125 billion euros. With a potential of global implementation, Trivisio's ARVisS system range will provide more accessible, yet strongly improved, accuracy, completeness and time efficiency in the surgical management of the common, high incidence, malignant cancer tissues. A novel approach is proposed implementing advanced microscopy, in combination with real-time fluorescence and 3D, in-sight image guidance by pre- and intraoperative diagnostic data. Bringing these three main benefits in a straightforward, easy-to-use fashion to the practicing surgeons, the proposed medical device has the potential to bridge the current gap between traditional surgical glass loupes with external information and high standard microscopy devices. Realization of this challenge is possible when Trivisio’s leading know-how and available state-of-the-art technologies, such as augmented reality and optical see-through head-mounted displays, are integrated in a simplified resection tool for healthcare. Higher success rates, time efficiency and subsequent financial cost of more common surgical interventions can then be achieved at only 25% of the current investment budget. Higher survival chances are aimed at by the decrease of post-operative side effects and a reduced cancer recurrence, leading to a lowering of the financial pressure on both medical institutions and national health care systems.

Wissenschaftliches Gebiet

• natural sciences › physical sciences › optics › microscopy
• medical and health sciences › clinical medicine › oncology › breast cancer
• medical and health sciences › clinical medicine › surgery › surgical procedures
• engineering and technology › materials engineering
• natural sciences › computer and information sciences › software › software applications › simulation software

Programm/Programme

• H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme
• H2020-EU.3.1.3. - Treating and managing disease

Thema/Themen

• PHC-12-2015-1 - Clinical research for the validation of biomarkers and/or diagnostic medical devices

Aufforderung zur Vorschlagseinreichung

H2020-SMEInst-2014-2015

Andere Projekte für diesen Aufruf anzeigen

Unterauftrag

H2020-SMEINST-1-2015

Finanzierungsplan

SME-1 - SME instrument phase 1

Koordinator

TRIVISIO PROTOTYPING GMBH

• Netto-EU-Beitrag: € 50 000,00
• Adresse: HERZOGENBUSCHER STRASSE 14 ; 54292 TRIER ; Deutschland
• KMU Die Organisation definierte sich zum Zeitpunkt der Unterzeichnung der Finanzhilfevereinbarung selbst als KMU (Kleine und mittlere Unternehmen). Ja:
  Region
  Rheinland-Pfalz › Trier › Trier, Kreisfreie Stadt
• Region: Rheinland-Pfalz › Trier › Trier, Kreisfreie Stadt
• Aktivitätstyp: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Gesamtkosten: € 71 429,00